Lakewood-Amedex Biotherapeutics (NASDAQ:LABT) Stock Rating Cut to “Strong Sell” at Wall Street Zen

Lakewood-Amedex Biotherapeutics (NASDAQ:LABT) was downgraded by equities researchers at Wall Street Zen from a “sell” rating to a “strong sell” rating in a report issued on Saturday, Wall Street Zen reports.

A number of other research firms have also recently commented on LABT. HC Wainwright began coverage on shares of Lakewood-Amedex Biotherapeutics in a report on Wednesday, October 28th. They issued a “buy” rating for the company. Weiss Ratings raised shares of Lakewood-Amedex Biotherapeutics from a “sell (e-)” rating to a “sell (e)” rating in a research note on Friday, October 2nd. One equities research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of “Hold”.

Lakewood-Amedex Biotherapeutics Stock Performance

LABT stock opened at $0.39 on Friday. Lakewood-Amedex Biotherapeutics has a twelve month low of $0.17 and a twelve month high of $98.20. The firm has a 50 day moving average of $1.19.

Lakewood-Amedex Biotherapeutics (NASDAQ:LABT) last announced its quarterly earnings results on Friday, August 14th. The company reported ($2.75) earnings per share (EPS) for the quarter. Equities research analysts anticipate that Lakewood-Amedex Biotherapeutics will post 4.96 EPS for the current fiscal year.

About Lakewood-Amedex Biotherapeutics

Lakewood-Amedex Biotherapeutics, Inc is a biotechnology company focused on the research and development of anti-infective therapies. Its work centers on developing treatments designed to address infections caused by bacteria and other pathogens.

The company’s activities are primarily directed toward advancing a pipeline of investigational therapeutic candidates rather than selling a broad portfolio of marketed products. Its development programs have focused on potential applications in human health, including treatments for localized and systemic infections.

Publicly available information about Lakewood-Amedex Biotherapeutics’ current product pipeline, commercial operations, geographic reach, and leadership is limited.